Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold J Burstein

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|September 16, 2011
Have we been down this road before?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2012
If the choices are all the same, why not prefer the less-expensive option?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2011
Texting the doctorHarold J Burstein
Breast (Edinburgh, Scotland)|October 22, 2011
Patients with anti-HER2 responsive disease: definition and adjuvant therapiesHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|May 25, 2010
Re-engineering the cooperative groupsHarold J Burstein
The New England Journal of Medicine|March 24, 2021
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. ReplyHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2012
Pathway-based oncology care: time for more transparencyHarold J Burstein
Cancer Investigation|March 5, 2008
Preoperative therapy as a model for translational research in breast cancerHarold J Burstein
Breast (Edinburgh, Scotland)|March 21, 2007
Aromatase inhibitor-associated arthralgia syndromeHarold J Burstein
The New England Journal of Medicine|October 21, 2005
The distinctive nature of HER2-positive breast cancersHarold J Burstein
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
Journal of the National Comprehensive Cancer Network : JNCCN|September 16, 2011
Have we been down this road before?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2012
If the choices are all the same, why not prefer the less-expensive option?Harold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2011
Texting the doctorHarold J Burstein
Breast (Edinburgh, Scotland)|October 22, 2011
Patients with anti-HER2 responsive disease: definition and adjuvant therapiesHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|May 25, 2010
Re-engineering the cooperative groupsHarold J Burstein
The New England Journal of Medicine|March 24, 2021
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. ReplyHarold J Burstein
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2012
Pathway-based oncology care: time for more transparencyHarold J Burstein
Cancer Investigation|March 5, 2008
Preoperative therapy as a model for translational research in breast cancerHarold J Burstein
Breast (Edinburgh, Scotland)|March 21, 2007
Aromatase inhibitor-associated arthralgia syndromeHarold J Burstein
The New England Journal of Medicine|October 21, 2005
The distinctive nature of HER2-positive breast cancersHarold J Burstein
Pageof 25